관상동맥 스텐트 : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2025-2030년)

The Coronary Stent Market size is estimated at USD 7.72 billion in 2025, and is expected to reach USD 9.51 billion by 2030, at a CAGR of 4.25% during the forecast period (2025-2030).

The coronary stent market is undergoing substantial growth, driven by several converging trends in the global healthcare landscape. The rising prevalence of cardiovascular diseases, combined with an aging global population and rapid advancements in cardiac stent technology, is fueling the demand for coronary stents. These factors are cultivating a conducive environment for market expansion, with specific drivers playing essential roles in shaping the industry's path forward.

Increasing Prevalence of Coronary Artery Diseases (CADs): The growing incidence of coronary artery diseases is a central factor in the expansion of the coronary stent market. As per the Centers for Disease Control and Prevention, approximately 20.1 million adults aged 20 and older in the U.S. suffer from coronary artery disease, accounting for 7.2% of the population. Globally, the World Heart Federation estimates that cardiovascular diseases, including heart disease and stroke, cause nearly 18.6 million deaths annually. This rising burden of CADs is translating directly into a greater demand for interventional cardiology devices like coronary stents, which are vital in addressing blocked or narrowed arteries.

Rising Geriatric Population: The global shift towards an aging population is also significantly influencing the coronary stent market. According to the United Nations' World Population Ageing report, the global geriatric population (aged 65 years or older) is projected to reach 1.5 billion by 2050, constituting 16% of the world's population. As older individuals are more prone to cardiovascular diseases, this demographic shift is expected to boost demand for coronary artery disease treatments. In the Asia-Pacific region, one-fourth of the population is expected to be 60 years or older by 2050, amplifying the demand for coronary stent market growth in this region.

Technological Advancements in Coronary Stents: The evolution of cardiac stent technology is playing a pivotal role in market growth. Recent innovations, such as bioresorbable stents and advanced drug-eluting stents (DES), are driving better patient outcomes. Medtronic's FDA-approved Onyx Frontier DES and SINOMED's HT Supreme DES highlight the ongoing strides in stent delivery and post-procedural safety. These advances not only improve the efficacy of coronary stents but also widen their applicability, including in more complex coronary interventions.

Coronary Stent Market Trends

Drug Eluting Stents (DES): Leading the Coronary Intervention Revolution Segment

Drug-eluting stents (DES) have solidified their position as a key player in coronary interventions, representing approximately 67% of the global coronary stent market. DES integrates structural support with the controlled release of medications to address restenosis. This innovative approach has become indispensable in modern cardiovascular care, resulting in fewer repeat procedures and enhanced patient outcomes.

Growth Drivers and Future Outlook: The growth of the DES segment is propelled by the increasing prevalence of coronary artery diseases, particularly among the elderly population. Advancements in drug-eluting stent technology and stent materials have significantly improved their safety and efficacy. Moreover, the ongoing shift towards minimally invasive procedures over open-heart surgeries is further driving the demand for DES. With research focusing on improving stent biocompatibility and reducing long-term complications, DES is expected to maintain its market dominance.

Competitive Landscape and Disruptions: In the highly competitive DES market, manufacturers are focusing on innovation. Thin-strut stents, biocompatible polymers, and novel drug combinations are some of the key areas driving competition. A potential disruptor to watch is the rise of bioresorbable stents, which could eventually challenge DES if they deliver comparable results. Companies must stay agile, investing in continuous innovation while preparing for shifts in treatment approaches.

Asia-Pacific: Epicenter of Coronary Stent Market Growth Regional Dynamics:

The Asia-Pacific coronary stent market is poised for rapid growth, with projections of a 9-10% compound annual growth rate (CAGR). This expansion is driven by a confluence of factors including a growing and aging population, rising incidence of cardiovascular diseases, and improvements in healthcare infrastructure.

Catalysts for Expansion: The rising incidence of lifestyle-related risk factors such as obesity, diabetes, and hypertension is contributing to the growth of the coronary stent market in the Asia-Pacific region. Additionally, increased awareness of the early detection and treatment of coronary artery diseases is driving demand for percutaneous coronary interventions (PCI). Government initiatives aimed at improving healthcare access, particularly in China and India, are also playing a vital role. The growth of medical tourism in countries like Thailand and Singapore further boosts the region's coronary stent market.

Strategic Imperatives and Future Challenges: To tap into the burgeoning Asia-Pacific coronary stent market, manufacturers are increasingly localizing their production and research activities. Collaboration with local healthcare providers and universities is also key to understanding regional needs and driving innovation. However, challenges such as government-imposed pricing regulations and competition from local manufacturers require companies to remain flexible and responsive to market dynamics.

Coronary Stent Industry Overview

Market Dynamics: Global Leaders in a Consolidated Landscape The global coronary stent market is characterized by a high degree of consolidation, with major players such as Abbott Laboratories, Medtronic, and Boston Scientific Corporation holding significant market share. These companies benefit from robust research and development capabilities, comprehensive product portfolios, and extensive global distribution networks. The market's consolidation is largely due to high entry barriers, such as stringent regulatory approvals and significant capital investment requirements.

Key Players: Innovation and Global Reach Drive Success Leading players like Abbott, Medtronic, and Boston Scientific consistently invest in innovation. For instance, Abbott's Xience Sierra DES has demonstrated superior outcomes in complex coronary cases. These firms' global manufacturing capabilities and strong relationships with healthcare providers enable them to maintain a competitive edge. Furthermore, their financial strength allows them to engage in strategic acquisitions, further consolidating their market positions.

Strategies for Future Success: To achieve continued success, leading market players must focus on developing next-generation stents that reduce procedural complications and improve long-term outcomes. The rise of bioresorbable stents is one such area showing promise in addressing long-term challenges. Additionally, expanding into emerging markets and investing in digital healthcare solutions, such as remote monitoring, can offer new growth opportunities.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Prevalence of Coronary Artery Diseases (CADs)
  • 4.2.2 Rising Geriatric Population
  • 4.2.3 Technological Advancements in Coronary Stents
• 4.3 Market Restraints
  • 4.3.1 High Product Recalls
  • 4.3.2 Stringent Approval Process for Stents
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD)

• 5.1 By Product Type
  • 5.1.1 Drug Eluting Stent
  • 5.1.2 Bare Metal Coronary Stent
  • 5.1.3 Bioabsorbable Stent
• 5.2 By Biomaterial
  • 5.2.1 Metallic Biomaterial
  • 5.2.2 Polymeric Biomaterial
  • 5.2.3 Natural Biomaterial
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Ambulatory Surgical Centers
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Abbott
  • 6.1.2 B. Braun SE
  • 6.1.3 Biosensors International Group Ltd
  • 6.1.4 BIOTRONIK SE & Co. KG
  • 6.1.5 Boston Scientific Corporation
  • 6.1.6 Cook Group
  • 6.1.7 Medtronic PLC
  • 6.1.8 Terumo Corporation
  • 6.1.9 Translumina GmbH
  • 6.1.10 Sahajanand Medical Technologies Limited
  • 6.1.11 Lepu Medical Technology (Beijing) Co.,Ltd.
  • 6.1.12 Bilakhia Holdings Pvt Ltd. (Meril Life Sciences)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS